Business
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized patients awaiting a kidney transplant and share perspectives on the clinical relevance of the topline results from the US Phase 3 ConfIdeS st
About this update from Hansa Biopharma Ab
[{"type":"text","content":"LUND, Sweden, Oct. 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized patients awaiting a kidney transplant and share perspectives on the clinical relevance of the topline results from the US Phase 3 ConfIdeS study. The event will take place on Wednesday 12 November, 2025, at 9:00 AM EST / 15:00 PM CET. Click here to join.","length":667,"tagName":"p"},{"type":"text","content":"After an introduction by Renée Aguiar-Lucander, CEO, Hansa Biopharma, there will be a presentation of the topline results from the US Phase 3 ConfIdeS trial by Richard Philipson, CMO. Philipson will then moderate a discussion reviewing current challenges of highly sensitized patients, the medical need and existing clinical practice for this patient group as well as the clinical relevance of the ConfIdes topline results, and the potential to impact current standard of care within the US transplant community with Dr. Robert Montgomery, MD, PhD, NYU Langone Transplant Institute, and Dr. Matthew Cooper, MD, Medical College of Wisconsin, followed by a Q&A session.","length":671,"tagName":"p"},{"type":"text","content":"About Robert Montgomery, MD, PhD","length":32,"tagName":"p"},{"type":"text","content":"Dr. Robert Montgomery is Chair of the Department of Surgery and Director of the NYU Langone Transplant Institute. As a pioneer and international expert in desensitization, he has taken part in numerous research studies, publications, and has received many awards for his work. Throughout his career, Dr. Montgomery has led innovation in transplantation, credited with developing and performing the first 'domino paired donation' and now leading efforts in xenotransplantation. He is also a heart transplant recipient himself. Dr Montgomery acted as Lead Principal Investigator for the ConfIdeS trial.","length":608,"tagName":"p"},{"type":"text","content":"About Matthew Cooper, MD","length":24,"tagName":"p"},{"type":"text","content":"Dr. Matthew Cooper is Chief of Transplantation, Director of Solid Organ Transplant, and th...